89bio Inc Ordinary Shares ETNB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ETNB is a good fit for your portfolio.
News
-
Madrigal's stock surges as FDA approves first drug for liver disease MASH
-
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?
-
Akero Therapeutics shares plunge on liver disease treatment's mixed results
-
89bio Gets FDA Breakthrough Designation for Pegozafermin in NASH
-
Weight-loss drugs in development aim to replace injections with pills
-
Oracle, Tesla, Anheuser-Busch stocks rise, Apple shares slip and other stocks on the move
-
89bio shares rise as analysts see improved outlook for NASH treatments
-
Bank ETFs stabilize but are still down on the week, Activision Blizzard's stock surges, and other stocks on the move
Trading Information
- Previous Close Price
- $9.18
- Day Range
- $9.03–9.34
- 52-Week Range
- $6.59–22.91
- Bid/Ask
- $9.04 / $9.07
- Market Cap
- $846.19 Mil
- Volume/Avg
- 187,879 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 70
- Website
- https://www.89bio.com
Comparables
Valuation
|
Metric
|
ETNB
|
PLRX
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.59 | 1.63 | 16.71 |
Price/Sales | — | 477.92 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ETNB
PLRX
DYN
Financial Strength
|
Metric
|
ETNB
|
PLRX
|
DYN
|
|---|---|---|---|
Quick Ratio | 19.55 | 17.43 | 2.41 |
Current Ratio | 20.04 | 17.72 | 2.53 |
Interest Coverage | −31.54 | −145.34 | — |
Quick Ratio
ETNB
PLRX
DYN
Profitability
|
Metric
|
ETNB
|
PLRX
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −28.69% | −22.68% | −88.69% |
Return on Equity (Normalized) | −32.35% | −24.50% | −114.25% |
Return on Invested Capital (Normalized) | −32.89% | −28.46% | −102.56% |
Return on Assets
ETNB
PLRX
DYN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Szxbfpvnc | Hbsb | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vddthysgn | Rwybpvl | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jwxqtxvmn | Xfckkb | $98.9 Bil | |
MRNA
| Moderna Inc | Lvftfjhkl | Mcvn | $39.7 Bil | |
ARGX
| argenx SE ADR | Bhclfqrqn | Vhzc | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Rdwccjnwh | Tlpd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fsjcxmkts | Wjvgs | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zgpwdlx | Glfzdq | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yxnqqzyqwc | Jsmvn | $12.3 Bil | |
INCY
| Incyte Corp | Mkrycpsv | Dqdcn | $11.8 Bil |